Truist Financial Issues Pessimistic Forecast for Medline (NASDAQ:MDLN) Stock Price

Medline (NASDAQ:MDLN) had its price objective decreased by stock analysts at Truist Financial from $56.00 to $47.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 33.51% from the company’s previous close.

Several other brokerages also recently issued reports on MDLN. Tigress Financial increased their price objective on Medline from $60.00 to $62.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. BNP Paribas Exane decreased their price objective on shares of Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. BTIG Research restated a “buy” rating and issued a $55.00 price objective on shares of Medline in a research note on Friday, July 31st. Barclays lowered their target price on shares of Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Monday, June 1st. Finally, Citigroup decreased their price target on shares of Medline from $60.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

Medline Stock Performance

Shares of Medline stock traded down $1.47 during trading hours on Thursday, hitting $35.20. 3,124,626 shares of the company were exchanged, compared to its average volume of 7,296,391. Medline has a 1 year low of $32.81 and a 1 year high of $50.88. The stock has a market capitalization of $46.25 billion and a price-to-earnings ratio of 110.02. The company has a current ratio of 4.41, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average of $38.29 and a 200-day moving average of $41.83.

Medline (NASDAQ:MDLN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.18. The firm had revenue of $7.68 billion for the quarter. As a group, analysts expect that Medline will post 1.49 EPS for the current fiscal year.

Insider Buying and Selling at Medline

In other news, insider Douglas P. Golwas sold 100,000 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total value of $3,677,000.00. Following the sale, the insider owned 23,899 shares of the company’s stock, valued at approximately $878,766.23. This represents a 80.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jessi L. Corcoran bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were purchased at an average price of $34.15 per share, with a total value of $170,750.00. Following the transaction, the insider directly owned 5,000 shares in the company, valued at $170,750. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.81% of the company’s stock.

Institutional Trading of Medline

Several large investors have recently added to or reduced their stakes in the company. Mass General Brigham Inc bought a new stake in Medline during the 4th quarter worth about $1,104,000. Sumitomo Mitsui Trust Group Inc. acquired a new position in Medline in the first quarter valued at approximately $1,177,000. Baillie Gifford & Co. bought a new position in Medline in the fourth quarter valued at approximately $437,236,000. Massachusetts Financial Services Co. MA acquired a new stake in Medline during the 4th quarter worth $429,544,000. Finally, UBS Group AG bought a new stake in shares of Medline in the 4th quarter valued at about $54,707,000.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter adjusted EPS of $0.50, above the $0.32 analyst consensus, while sales rose 11.6% year over year to $7.7 billion. Adjusted EBITDA increased 13.4% to $1.06 billion, and management raised full-year organic sales growth guidance to 9%-10%. Medline Reports Second Quarter and First Six Months 2026 Results
• Positive Sentiment: BTIG analyst David Larsen reiterated a Buy rating and maintained a $55 price target, citing robust growth and viewing current headwinds as transitory. BTIG Medline Rating
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but lowered its price target from $50 to $45, reflecting more cautious expectations while still implying substantial potential upside from recent levels. Benzinga analyst report
• Negative Sentiment: Medline reduced its full-year adjusted EBITDA outlook to $3.3-$3.4 billion from $3.5-$3.6 billion. Management cited inflation, higher investment and remediation costs, retail-channel softness, and the operating impact of the Tracy, California distribution-center fire. The fire contributed to $336 million in losses, helping drive a 58.3% decline in quarterly net income to $139 million. Medline updates 2026 outlook
• Negative Sentiment: A law firm announced an investigation into possible securities-law violations involving Medline. The announcement is preliminary and does not establish wrongdoing, but it adds headline and litigation risk. Kaplan Fox investigation announcement

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.